October Term 2010 · Docket 09-1156

Does a single adverse report require a drug maker to disclose?

Investors sue a drug maker for hiding a single adverse report. The company argues the report lacked scientific proof.

Official caption
Matrixx Initiatives v. Siracusano
Latest argument session
Latest official Court activity
Latest verified event
Argued
Sources analyzed through
Official Transcript

Verified source milestones

  1. — An official oral-argument transcript was verified.
  2. — An official oral-argument transcript was verified.

The arguments, in order

This case may have been argued more than once. Each entry below uses that session's official transcript. Later arguments do not erase earlier ones.

  1. Argument 1 ·

    What happened at the argument

    Mr. Frederick argued that materiality depends on the total mix of information.

    Mr. Hacker stated that drug companies receive many anecdotal reports daily.

    Mr. Shah argued that precedents require a meaningful alteration of the total mix.

    Read the official transcript for this argument · Official argument details

    Sources used for this argument breakdown

A citizen's guide to the whole case

What this case is about

This case tests when a company must disclose a single adverse report. The dispute centers on the legal standard for materiality in securities fraud.

Official sources for this section

How the case got here

The Supreme Court heard oral argument in this case on January 10, 2011.

Official sources for this section

What each side wants

The company wants the Court to require proof of scientific significance before disclosure.

The investors want the Court to allow disclosure based on the total mix of information.

Official sources for this section

What each side says

The company argues that a single report lacks scientific plausibility and is not material.

The investors argue that the total mix of information makes the report material to investors.

Official sources for this section

What the justices asked

Justice Sotomayor asked if the source of the report changes its materiality.

Justice Kennedy asked if a baseless claim still requires disclosure if the market reacts.

Official sources for this section

Why it matters

This case defines when companies must disclose adverse reports. It affects how investors evaluate drug company risks. It shapes the balance between scientific proof and market reaction.

Official sources for this section

What happens next

This article currently covers the argument record. Use the official docket link for later case activity.

Official sources for this section

Official Court provenance

Official docket and case history · Official Supreme Court oral-argument detail page

Title and summary sources

Revision history

  1. Revision 1 · Official Transcript ·

    Correction: Rewritten to the concise citizen-facing editorial standard.

  2. Revision 2 · Official Transcript ·

    Correction: Migrated to the dated official Court activity contract without model use.

Download this sanitized case as JSON